Mezigdomide History and Updates

55 events · 2015 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
55
Trial Milestones
0
Pivotal Publications
Mezigdomide — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications201520162017201820192020202120222023202420252026202720282029Trial: NCT07355335 2026-07-09 → 2027-07-01 (primary completion)Trial: NCT07356154 2026-01-16 → 2029-01-16 (primary completion)Trial: NCT07032714 2025-12-19 → 2027-07-01 (primary completion)Trial: NCT06988488 2025-10-07 → 2027-05-31 (primary completion)Trial: NCT07105059 2025-08-08 → 2028-08-08 (primary completion)Trial: NCT06627751 2025-05-01 → 2027-05-01 (primary completion)Trial: NCT06645678 2024-11-26 → 2026-10-01 (primary completion)Trial: NCT06048250 2024-04-09 → 2026-09-21 (primary completion)Trial: NCT06318676 2024-03-21 → 2024-11-15 (primary completion)Trial: NCT06163898 2024-02-27 → 2025-06-03 (primary completion)Trial: NCT06121843 2024-02-22 → 2028-08-01 (primary completion)Trial: NCT05981209 2023-12-21 → 2026-12-31 (primary completion)Trial: NCT06050512 2023-10-02 → 2026-10-31 (primary completion)Trial: NCT05651932 2023-02-22 → 2027-12-31 (primary completion)Trial: NCT05707390 2023-02-20 → 2023-09-13 (primary completion)Trial: NCT05552976 2023-01-10 → 2026-07-18 (primary completion)Trial: NCT05519085 2022-09-20 → 2027-01-10 (primary completion)Trial: NCT02343042 2015-10-31 → 2027-04-30 (primary completion)today (2026-06-11)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-11Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Mezigdomide since 2015, drawn from openFDA, ClinicalTrials.gov, and PubMed.

Upcoming & expected milestones

Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT05552976
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Part
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05981209
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participan
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT06627751
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Dis
Primary completion· ClinicalTrials.gov
Phase 1/Phase 2 primary completion: NCT06988488
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participa

Past events

2026
2025
Trial started· ClinicalTrials.gov
Phase 1/Phase 2 trial started: NCT06988488
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06163898
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT06627751
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Dis
2024
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06048250
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06318676
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06163898
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participa
2023
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT05981209
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT05552976
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Part
2022
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participan
2015

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.